McDermott Welcomes Prominent Food & Drug Administration Practitioner to Washington, D.C. Office
WASHINGTON, D.C. (February 4, 2008) — The Washington, D.C. office of McDermott Will & Emery is delighted to announce Arnold I. Friede has joined as counsel in the Firm's Health Law Department. Mr. Friede most recently served as a senior corporate counsel at Pfizer, Inc. in New York, and also formerly served as an associate chief counsel in the U.S. Food & Drug Administration (FDA) chief counsel's office. He is a widely respected food and drug law counselor and advocate, with significant advertising law, health care law, First Amendment, environmental, and commercial and transactional experience. He has a long history of direct involvement in successfully representing clients in FDA-regulated matters.
"Arnie brings a breadth and depth of experience developed over nearly 35 years," commented Michael Anthony, head of the Firm's international Health Law Department. "With Arnie's arrival, as well as Eric Hargan's recent move to McDermott, we have significantly enhanced our Firm-wide pharmaceutical industry practice, as well as our FDA practice, led by Robert B. Nicholas in our D.C. office, that is increasingly becoming a global need for our clients."
Mr. Friede has substantial experience across a broad range of FDA-regulated industries, including, but not limited to, pharmaceuticals and biological products, food (including dietary supplements), over-the-counter drugs, cosmetics and medical devices. He has extensive knowledge in all aspects of the FDA's and other agency regulation of pharmaceutical advertising and promotion. Additionally, he has significant experience in analyzing and responding to FDA advertising compliance correspondence.
"As a leading lawyer in the pharmaceutical industry, Arnie is key to our continually expanding FDA and pharmaceutical industry team," said Joel L. Michaels, partner-in-charge of the Health Law Department in McDermott's Washington, D.C. office.
Mr. Friede also has significant First Amendment experience in the context of speech regulation concerning FDA-regulated products, and has authored several articles on the subject. His background additionally includes product liability and class action consumer fraud litigation involving the pharmaceutical industry.
Among other areas, Mr. Friede has considerable experience in FDA's regulation of brand versus generic drugs, including the authorized generics controversy, and in the antitrust issues relating to settlements of brand versus generic Hatch-Waxman litigation. He is experienced in FDA regulation governing early access to experimental drugs, notably experimental oncology drugs. He has assisted in the development and implementation of life cycle strategies for pharmaceuticals, from discovery through FDA approval to patent expiry and beyond. Mr. Friede worked on numerous pharmaceutical licensing, co-promotion, joint venture, and similar agreements in the pharmaceutical industry and has strong due diligence experience. Mr. Friede has substantial experience in the field of disease management, and previously served as counsel for Pfizer's disease management subsidiary.
Mr. Friede earned his J.D., Order of the Coif, from the George Washington University School of Law and his B.S. in mathematics with honors, from the University of Pittsburgh. He is admitted to the State Bars of California, Connecticut, the District of Columbia, and Maryland.
Mr. Friede is a member of the Administrative Law Section/Food, Drug, Cosmetic of the American Bar Association. He is a former chair of the Government Relations Committee for the Cosmetic Toiletry and Fragrance Association. He is a former member of the Editorial Advisory Board of the Food Drug Cosmetic Drug Law Journal and is also a former member of the Advisory Board of Trustees for the Food and Drug Law Institute. Mr. Friede previously served as chair of the Food, Drug, Cosmetic Law Section of the New York State Bar Association. He was co-founder of the Greater Chicago Food and Drug Law Association. He has served on numerous other industry committees over the course of his impressive career.
With an over 50-year history of serving the health care industry, McDermott has one of the United States' largest and most prestigious health law departments. Our international health team counsels leading organizations in every major sector of the health care industry on regulatory and business transaction issues. Additionally, our Life Sciences & Medical Devices Practice Group provides a fully integrated, multidisciplinary legal services to the life sciences industry. Our group of 75+ lawyers, patent agents and scientific advisors provides the full range of legal services required by life sciences companies, regardless of their stage of development.
